AnneFitzfaReillyMD

Pediatric Hematology & Oncology • Philadelphia, PA

Professor, Pediatrics, Perelman School of Medicine

Join to view full profile

Are you Dr. Reilly?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 77 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
3401 Civic Center Blvd
Chca Hematology & Oncology
Philadelphia, PA 19104
Phone+1 215-590-3535

Fax+1 215-590-3992

Summary

Dr. Anne Reilly, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania, New York, and New Jersey. She is affiliated with Children's Hospital of Philadelphia and is a Professor at Perelman School of Medicine.

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1993
Sidney Kimmel Medical College at Thomas Jefferson University/Nemours Children's Health, WilmingtonResidency, Pediatrics, 1987 - 1990
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1987

Certifications & Licensure

NJ State Medical License 2000 - 2025
NY State Medical License 2015 - 2025
PA State Medical License 1990 - 2024
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Completed
Phase 2

Publications & Presentations

PubMed

46 citations
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Eric J. Lowe, Anne Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig
Blood. 2021-07-01
12 citations
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.
Michael P Triebwasser, David M. Barrett, Hamid Bassiri, Nancy Bunin, Caitlin W Elgarten
Pediatric Blood & Cancer. 2021-03-22
127 citations
Classifying the intensity of pediatric cancer treatment protocols: The intensity of treatment rating scale 2.0 (ITR-2)
Branlyn E. Werba, Wendy L. Hobbie, Anne E. Kazak, Richard F. Ittenbach, Anne F. Reilly
Pediatric Blood & Cancer. 2007-06-15